Literature DB >> 28238091

Patient-reported symptoms of radiation dermatitis during breast cancer radiotherapy: a pilot study.

Jieun Lee1, Won Park2, Doo Ho Choi1, Seung Jae Huh1, Im-Ryung Kim3, Danbee Kang4, Juhee Cho3,4,5.   

Abstract

PURPOSE: To find out which symptoms most frequently and severely affect breast cancer patients during radiotherapy and how patients manage the symptoms and unmet needs.
METHODS: A cross-sectional survey was conducted with 111 patients who receive radiotherapy for breast cancer from January to April 2015 at Samsung Medical Center in Seoul, South Korea. Participants were asked about symptoms and discomfort due to radiotherapy, management methods for radiation dermatitis, unmet needs for radiation dermatitis care, and clinical and socio-demographic information.
RESULTS: Of total, 108 out of 111 patients (97.3%) reported symptoms related to radiation dermatitis. Hyperpigmentation was the most commonly reported uncomfortable symptom followed by erythema. On average, patients reported 8.6 radiotherapy-induced skin problems (range, 0-11). Of total, 59 (53.2%) patients stated that they wanted care for radiation dermatitis, and 80.0, 59.4, and 51% of patients searched for information, used products, and visited the hospital to manage radiotherapy-related skin problems. Patients who experienced dryness, burning feelings, irritation, roughness, and hyperpigmentation were 11.73, 7.02, 5.10, 4.27, and 2.80 times more likely to have management needs than patients without those symptoms, respectively, adjusting age, current cycle of radiation therapy, chemotherapy, and type of surgery.
CONCLUSIONS: Most of the breast cancer patients experience multiple symptoms associated with radiation dermatitis. Hyperpigmentation was the most common and uncomfortable symptom followed by erythema. Majority of patients wanted management for radiation dermatitis and patients who experienced dryness, burning feelings, irritation, roughness, and hyperpigmentation had higher needs for radiation dermatitis management.

Entities:  

Keywords:  Breast neoplasms; Quality of life; Radiodermatitis; Radiotherapy

Mesh:

Year:  2017        PMID: 28238091     DOI: 10.1007/s11136-017-1526-4

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  2 in total

Review 1.  Radiation burn--from mechanism to management.

Authors:  Chaitali Manohar Waghmare
Journal:  Burns       Date:  2012-10-23       Impact factor: 2.744

Review 2.  Patient-reported Outcome Measures in Radiotherapy: Clinical Advances and Research Opportunities in Measurement for Survivorship.

Authors:  S Faithfull; A Lemanska; T Chen
Journal:  Clin Oncol (R Coll Radiol)       Date:  2015-09-28       Impact factor: 4.126

  2 in total
  14 in total

1.  Association Between Inflammatory Biomarker C-Reactive Protein and Radiotherapy-Induced Early Adverse Skin Reactions in a Multiracial/Ethnic Breast Cancer Population.

Authors:  Jennifer J Hu; James J Urbanic; L Doug Case; Cristiane Takita; Jean L Wright; Doris R Brown; Carl D Langefeld; Mark O Lively; Sandra E Mitchell; Anu Thakrar; David Bryant; Kathy Baglan; Jon Strasser; Luis Baez-Diaz; Glenn J Lesser; Edward G Shaw
Journal:  J Clin Oncol       Date:  2018-07-10       Impact factor: 44.544

2.  A novel carbon-fibre adjustable reusable accessory (CARA) for supine breast positioning to reduce toxicity in breast adjuvant radiotherapy: a study protocol for a multicentre phase III randomized controlled trial.

Authors:  Cheryl Duzenli; Elisa K Chan; Alanah M Bergman; Sheri Grahame; Joel Singer; Levi Burns; Robert A Olson
Journal:  BMC Cancer       Date:  2022-06-20       Impact factor: 4.638

3.  Cancer Cell-Erythrocyte Hybrid Membrane Coated Gold Nanocages for Near Infrared Light-Activated Photothermal/Radio/Chemotherapy of Breast Cancer.

Authors:  Mengqi Sun; Yuchen Duan; Yumeng Ma; Qingyuan Zhang
Journal:  Int J Nanomedicine       Date:  2020-09-11

4.  A Retrospective Analysis of Dose Distribution and Toxicity in Patients with Left Breast Cancer Treated with Adjuvant Intensity-Modulated Radiotherapy: Comparison with Three-Dimensional Conformal Radiotherapy.

Authors:  Chia-Hsin Chen; Ching-Chuan Hsieh; Chih-Shen Chang; Miao-Fen Chen
Journal:  Cancer Manag Res       Date:  2020-09-28       Impact factor: 3.989

5.  Radiation dermatitis assessment tools used in breast cancer: A systematic review of measurement properties.

Authors:  Tara Behroozian; Lauren T Milton; Neil H Shear; Erin McKenzie; Yasmeen Razvi; Irene Karam; Kucy Pon; Henry Lam; Emily Lam; Edward Chow
Journal:  Support Care Cancer       Date:  2020-11-17       Impact factor: 3.603

6.  Topical Application of Phlorotannins from Brown Seaweed Mitigates Radiation Dermatitis in a Mouse Model.

Authors:  Kyungmi Yang; Shin-Yeong Kim; Ji-Hye Park; Won-Gyun Ahn; Sang Hoon Jung; Dongruyl Oh; Hee Chul Park; Changhoon Choi
Journal:  Mar Drugs       Date:  2020-07-22       Impact factor: 5.118

7.  X-ray induces mechanical and heat allodynia in mouse via TRPA1 and TRPV1 activation.

Authors:  Su Cun-Jin; Xu Jian-Hao; Liu Xu; Zhao Feng-Lun; Pan Jie; Shi Ai-Ming; Hu Duan-Min; Yu Yun-Li; Liu Tong; Zhang Yu-Song
Journal:  Mol Pain       Date:  2019 Jan-Dec       Impact factor: 3.395

8.  Damage to sebaceous gland and the efficacy of moisturizer after whole breast radiotherapy: a randomized controlled trial.

Authors:  Mami Ogita; Kenji Sekiguchi; Keiko Akahane; Ryoko Ito; Chiori Haga; Satoru Arai; Yasushi Ishida; Jiro Kawamori
Journal:  BMC Cancer       Date:  2019-02-07       Impact factor: 4.430

9.  Silencing of XRCC4 increases radiosensitivity of triple-negative breast cancer cells.

Authors:  Yuqing Wen; Gongpeng Dai; Liping Wang; Kanda Fu; Shuguang Zuo
Journal:  Biosci Rep       Date:  2019-03-19       Impact factor: 3.840

10.  Efficacy of heparinoid moisturizer as a prophylactic agent for radiation dermatitis following radiotherapy after breast-conserving surgery: a randomized controlled trial.

Authors:  Kenji Sekiguchi; Keiko Akahane; Mami Ogita; Chiori Haga; Ryoko Ito; Satoru Arai; Yasushi Ishida; Yoichiro Tsukada; Jiro Kawamori
Journal:  Jpn J Clin Oncol       Date:  2018-05-01       Impact factor: 3.019

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.